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Abstract (300 words) 
Introduction 
Proximal femoral (hip) fracture is common, serious and costly. Rehabilitation may improve 
functional recovery but evidence of effectiveness and cost-effectiveness is lacking. An 
enhanced rehabilitation intervention was previously developed and a feasibility study tested 
the methods used for this randomised controlled trial (RCT).  
The objectives are to compare the effectiveness and cost-effectiveness of the enhanced 
rehabilitation programme following surgical repair of proximal femoral fracture in older 
people compared with usual care. 
Methods and analysis 
Protocol for phase III, parallel-group, two-armed, superiority, pragmatic RCT with 1:1 
allocation ratio. Allocation sequence by minimisation programme with a built in random 
element. Secure web-based allocation concealment. The two treatments will be usual care 
(control) and usual care plus an enhanced rehabilitation programme (intervention). The 
enhanced rehabilitation will consist of a patient-held information workbook, goal-setting 
diary and up to six additional therapy sessions. Outcome assessment and statistical analysis 
will be performed blind; patient and carer participants will be unblinded. Outcomes will be 
measured at baseline, 17 and 52 weeks’ follow-up. Primary outcome at 52 weeks will be the 
Nottingham Extended Activities of Daily Living scale. Secondary outcomes will measure 
anxiety and depression, health utility, cognitive status, hip pain intensity, falls self-efficacy, 
fear of falling, grip strength and physical function. Carer strain, anxiety and depression will 
be measured in carers. All safety events will be recorded, and serious adverse events will be 
assessed to determine whether they are related to the intervention and expected.  
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Concurrent economic evaluation will be a cost-utility analysis from a health service and 
personal social care perspective. An embedded process evaluation will determine the 
mechanisms and processes that explain the implementation and impacts of the enhanced 
rehabilitation programme. 
Ethics and dissemination 
NHS research ethics approval reference 18/NE/0300. Results will be disseminated by peer-
reviewed publication. 
Registration details  
ISRCTN28376407 registered on 23/11/2018. 
 
Article Summary 
Strengths and limitations of this study 
• Pragmatic phase III randomised controlled trial following phase I intervention 
development and phase II feasibility study. 
• Concurrent economic evaluation with a health service and personal social care 
perspective.  
• Embedded process evaluation to determine the mechanisms and processes that 
explain the implementation and impacts of the enhanced rehabilitation programme. 
• Only patients with mental capacity to consent are eligible, therefore excluding a 
large number of potential participants lacking capacity. 
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Introduction 
Proximal femoral fracture, more commonly referred to as hip fracture, is a common, major 
health problem in old age [1]. It is projected to increase further as the population ages [2,3]. 
Mortality is high [4,5], and of those who survive to one year, 29% fail to regain their level of 
functioning, in terms of restrictions of activities of daily living [6]; many lose their 
independence. This imposes a large cost burden on society, estimated to be approximately 
£2.3 billion a year in the United Kingdom [7]. The majority of costs are incurred in the 
community and social care setting in the 12 months following hospital discharge, which are 
almost four times higher than the costs of the acute hospital admission [8]. Frail individuals 
are at particular risk of secondary future proximal femoral fracture, resulting in worse 
morbidity and mortality outcomes [9]. 
 
The National Institute of Health and Clinical Excellence (NICE) have issued guidelines for the 
management of hip fracture [10]. This includes the provision of a co-ordinated 
multidisciplinary rehabilitation programme starting in hospital during post-operative 
recovery and continuing in the community following discharge [10]. Where possible such 
rehabilitation programmes should consider individual patient goals, facilitate a return to 
pre-fracture independence and provide patients and carers with written information to 
support the rehabilitation programme and long-term outcomes. The Hip Sprint audit 
reported that community rehabilitation services were inconsistent [11]. 
 
Rationale  
There have been four relevant Cochrane systematic reviews with inconclusive results [12-
15]. These have examined different types and intensities of in-patient rehabilitation [12], 
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mobilisation strategies [13], psychosocial functioning after hip fracture [14] and 
rehabilitation for those with dementia following hip fracture surgery [15]. Other systematic 
reviews have reported improved walking ability [16], strength and physical function [17], 
including those with mild to moderate dementia [18]. These systematic reviews concluded 
that whilst individual components of rehabilitation programmes may aid recovery after a hip 
fracture, there is insufficient evidence to demonstrate clinical effectiveness or cost-
effectiveness of an overall care pathway, and that further research is required. 
 
A previous study [19] completed the first two phases of the Medical Research Council (MRC) 
framework for complex interventions [20]. The first phase developed an enhanced 
rehabilitation intervention which, in addition to usual care, included a patient-held 
workbook, a goal-setting diary and up to six additional home-based therapy sessions [21]. 
The second phase of the study was a randomised feasibility study, which assessed the 
acceptability of the new rehabilitation programme and the feasibility of trial methods for a 
definitive phase III randomised controlled trial (RCT) [22, 23]. Although this feasibility study 
was underpowered to assess effectiveness, the intervention showed a medium sized 
improvement in the Nottingham Extended Activities of Daily Living scale compared with 
usual care (Cohen’s d 0.63). A process evaluation described the implementation of the 
rehabilitation programme and informed how to enhance recruitment and improve the 
intervention [24]. 
 
Risk and Benefits 
The enhanced rehabilitation programme demonstrated a potential improvement in 
activities of daily living in the feasibility study. Possible risks of rehabilitation interventions 
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would include injury or falling when performing therapeutic exercises, which must be 
weighed against the risk to health of sedentary behaviour.  
 
Primary Objective  
To determine the effectiveness of an enhanced rehabilitation programme following surgical 
repair of proximal femoral fracture in older people compared with usual care, in terms of 
the performance of activities of daily living at 52 weeks follow-up.  
 
Secondary Objectives 
1. To compare the cost-effectiveness of an enhanced rehabilitation programme 
following surgical repair of proximal femoral fracture in older people compared with 
usual care at 52 weeks follow-up.  
2. To determine the effectiveness of an enhanced rehabilitation programme following 
surgical repair of proximal femoral fracture in older people compared with usual 
care, in terms of the performance of activities of daily living at 17 weeks follow-up. 
3. To determine the effectiveness of an enhanced rehabilitation package following 
surgical repair of proximal femoral fracture in older people compared with usual 
care, in terms of anxiety and depression at 17 and 52 weeks follow-up. 
4. To assess whether the enhanced rehabilitation intervention creates change in self-
efficacy, hip pain, cognitive function, fear of falling and physical function as potential 
mediators for improving activities of daily living at 17 and 52 weeks follow-up. 
5. To assess whether the enhanced rehabilitation intervention creates change in strain, 
anxiety and depression in carers at 17 and 52 weeks follow-up. 
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6. To determine the mechanisms and processes that explain the implementation and 
impacts of the enhanced rehabilitation programme, and whether there are adverse 
effects. 
 
Methods and Analysis 
Trial design 
This is a pragmatic, multisite, parallel-group, two-armed, superiority randomised controlled 
trial (RCT) with 1:1 allocation ratio, and an internal pilot phase (Figure 1). Outcome 
assessment and statistical analysis will be blinded; patient and carer participants and 
clinicians will be unblinded. A concurrent economic evaluation will be a cost-utility analysis 
from a health service and personal social care perspective. An embedded process evaluation 
will examine the mechanisms and processes that explain the implementation and impacts of 
the enhanced rehabilitation programme. 
 
Trial Setting and Selection of Sites / Clinicians  
Sites were recruited by co-investigators in different regions of England and Wales with a 
spread of socio-economic conditions and a mixture of rural and urban locations: Kent (CS), 
Merseyside (NW), Norwich (TS), north Wales (RL), Nottingham (PL) and south Wales (MB). 
The sites had to include trauma centres treating proximal femoral fracture and links to 
community rehabilitation teams, which could accommodate the extra community 
rehabilitation sessions. 
Patients will be recruited on orthopaedic, rehabilitation and community hospital wards, or 
after hospital discharge home. The intervention will be delivered in the community, 
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following hospital discharge, by community teams receiving referrals from the acute 
hospital sites and their associated community hospitals.  
Selection of Sites/Clinicians  
Sites have been opened to recruitment in Nottingham, Norfolk, north Wales, south Wales 
and east Kent. Further sites are planned in west Kent, Derby and Cheshire plus others. The 
site trial teams comprise principal investigators, hospital and community NHS staff, research 
assistants and support staff from clinical research networks. 
 
Trial Population 
Inclusion Criteria 
1. Age 60 years or older 
2. Recent proximal femoral fracture  
3. Surgical repair by replacement arthroplasty, hemi-arthroplasty or internal fixation 
4. Living in their own home prior to hip fracture 
5. Living and receiving rehabilitation from the NHS in the area covered by the trial sites 
Exclusion Criteria  
1. Living in residential or nursing homes prior to hip fracture 
2. Participants unable to understand English or Welsh 
3. Lacking mental capacity to give informed consent 
Carer Participants 
We will also recruit carer participants to evaluate carer strain, anxiety and depression. These 
are defined as a relative or friend providing help with activities of daily living or physical 
care, at least four days a week. Carer participants will provide informed consent, but will not 
receive any trial intervention, so will not undergo eligibility screening or randomisation. 
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Trial Treatment/interventions 
We plan to compare an enhanced rehabilitation intervention with usual rehabilitation care.  
Usual rehabilitation care 
Usual care consists of a multi-disciplinary rehabilitation delivered by the acute hospital, 
community hospital and community services depending on patients’ individual needs at 
different times during their recovery and on the availability and accessibility of services in 
different areas. The multidisciplinary team delivering care and rehabilitation may include: 
orthopaedic surgeons, orthogeriatricians, nurses, physiotherapists, occupational therapists, 
dieticians, pharmacists, GPs and social workers.  The settings for care include acute 
orthopaedic or orthogeriatric wards, rehabilitation units in community hospitals, 
rehabilitation beds in care homes, the patient’s own home and care home settings, all 
delivered by a variety of community teams in both health and social care services. There will 
be no restrictions on concomitant medications or treatments.  
Enhanced rehabilitation 
The main aim of the intervention is to enhance usual rehabilitation by increasing patients’ 
self-efficacy [25], and increasing the amount and quality of patients’ practice of physical 
exercise and activities of daily living to improve functional outcomes at follow-up. Self-
efficacy will be enhanced by means of a patient-held information workbook and a goal-
setting diary.  The workbook will include:  
• Information about what has happened to them, and what to expect from their 
recovery;  
• Information about NHS, council and voluntary sector services including falls’ 
prevention programmes;  
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• How to manage their recovery, set goals and monitor progress of their rehabilitation; 
reduce fear of falling.  
In addition to whatever community-based rehabilitation is provided as part of usual care, 
we will provide up to six additional therapy sessions, once patients are discharged home. 
These can be delivered by physiotherapists, occupational therapists or their assistants, who 
have been trained to deliver these extra sessions alongside the workbook, using the diary to 
set goals and monitor progress. The therapists will tailor these extra sessions, so that the 
total number of sessions used, the time scale for their delivery, and the sessions’ content 
will vary between patients according to need, but may include the practice of specific 
exercises and activities of daily living. Throughout the running of this trial, therapists will 
receive on-going support via e-mails, newsletters and refresher events.                                                                                                                                                                        
 
Outcomes 
Patient participants will complete outcome measures at baseline, 17 and 52 weeks 
administered by a research assistant blinded to participant allocation. Follow-up 
assessments will be completed within participants’ homes (Tables 1 and 2). The primary 
outcome will be the difference in Nottingham Extended Activities of Daily Living (NEADL) 
scale [26,27] at 52 week follow-up, between the usual rehabilitation arm and the enhanced 
rehabilitation arm. At baseline, the patient will be asked to recall the four weeks prior to hip 
fracture and not four weeks prior to completing this questionnaire. Secondary outcomes will 
include the Hospital Anxiety and Depression Scale (HADS) [28], economic measures will be 
EuroQol EQ-5D-3L [29] and Client Service Receipt Inventory (CSRI) [30]. A reduced version of 
this will be used at baseline to reduce participant burden as they recover from hip fracture 
surgery. Potential mediators of outcome will include a Visual Analogue Scale (VAS) for hip 
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pain intensity [31], Falls Efficacy Scale - International (FES-I) (self efficacy) [32,33], and Visual 
Analogue Score - Fear of Falling (VASFoF) [34]. 
 
The research assistant will assess patient participants’ cognitive function at baseline, 17 and 
52 weeks using the Abbreviated Mental Test Score (AMTS) [35]. The research assistant will 
measure physical function at baseline, 17 and 52 weeks using the grip strength test [36-38], 
and using the Short Physical Performance Battery (SPPB) [39,40] at 17 and 52 weeks.  
Carer participants will complete the Caregiver Strain Index (CSI) [41] and the Hospital 
Anxiety and Depression Scale (HADS) [28] at baseline, 17 and 52 weeks. 
 
Qualitative interviews will take place with patients and carers after 17 weeks. These will 
gather data on trial participation and intervention design (see process evaluation below).  
 
Routinely collected demographic, clinical and recruitment data will include the numbers of 
patients who are eligible, willing to be randomised, withdraw after randomisation, complete 
outcome measurements, also reasons for non-completion, age, gender, hip fracture type, 
surgery type, co-morbid conditions, place of residence prior to admission and place of 
discharge. 
 
Sample size calculation  
The phase II feasibility study results [23] informed the sample size calculation. The adjusted 
mean difference in the primary outcome measure (NEADL) between the intervention and 
control group in the feasibility trial was 3.0. Work completed by Wu, et al [27] has suggested 
that the minimum clinically significant difference is 2.4; this has been used within the 
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sample size calculation for this phase III RCT. A two-point score in the NEADL scale would 
equate to an improvement in function from being independent around the home to being 
able to use public transport or get in and out of a car. The adjusted mean difference 
between the groups in NEADL in the randomised feasibility study had a standard deviation 
(SD) of 5.8. In this multi-site phase III RCT, a more diverse sample would be expected, so a 
larger SD would be expected. Parker et al. [42] used NEADL in a rehabilitation RCT and found 
a SD of 10. Based on ANCOVA with alpha of 5% and 90% power to detect a difference of 2.4 
(SD = 10, R2 of covariate = 0.52) 352 patient participants would be required to complete the 
trial over both treatment groups. When considering the 79% retention rate in the feasibility 
study [23], the trial would need to recruit 446 patient participants. 
 
Recruitment and Randomisation 
Screening and Consent – Patient Participants 
Patients with proximal femoral fracture will be identified and screened for eligibility, 
including mental capacity, by clinical staff on orthopaedic or rehabilitation wards. If the 
patients are eligible, and interested in the trial, the trial team researchers would then 
recruit patients following the trial’s informed consent process. Assessment of eligibility may 
occur over an extended period, if for example, the patient is experiencing temporary 
delirium post-surgery.  If during this period, patients are transferred to rehabilitation wards, 
community hospitals, or discharged home, then assessment will continue in these 
alternative locations. These assessments will be recorded in a screening log, including any 
reasons for ineligibility.  
Informed consent - carer participants 
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For the purpose of this RCT, carers are defined as either a relative or friend caring for a hip 
fracture patient, helping them with activities of daily living or physical care on at least four 
days a week. They will be identified and recruited following the trial’s informed consent 
process. Copies of the participant information sheets and informed consent forms can be 
found in Appendices 1 and 2 in the supplementary file. 
Randomisation Procedures  
Patient participants who provide informed consent will complete baseline outcome 
measurements prior to randomisation. Randomisation will take place no later than six 
weeks after hip fracture repair surgery. The randomisation will have an allocation ratio of 
1:1 within each stratum and across the trial. Randomisation will use a minimisation 
programme with a built in random element utilising factors that will not be made known to 
individuals in charge of recruitment to minimise any potential for predicting allocation. 
Randomisation will be completed by secure web access to the remote randomisation site at 
the clinical trials unit. The therapists delivering the enhanced rehabilitation intervention will 
receive an automated email when a participant has been allocated to the intervention 
group. 
Blinding 
This is a pragmatic trial comparing two rehabilitation interventions. It will therefore not be 
possible to blind participants or their clinicians to treatment group allocation. The research 
assistants will collect outcome measurements blind to treatment allocation. They will not be 
informed to which group the patient participants have been allocated, and will not be 
present at any of the therapy sessions. Before any home visits for follow-up assessments, 
they will ask participants not to reveal their treatment allocation. After the final follow-up 
assessment, they will complete a perception of allocation form, in order to monitor the level 
 16 
 
of blinding achieved for these researchers. Data analysis will be performed blind to 
treatment allocation. 
 
Internal pilot 
An internal pilot assessed site recruitment and participant recruitment and retention rates 
for the six months after the first site was open to recruitment from September 2019 to 
February 2020.  
Progression criteria 
• Number of sites open: 7 or more (go); 5-6 (amend); 4 or fewer (stop) 
• Open site recruitment rate per month: 2 or more (go); 1-2 (amend); <1 (stop) 
• Retention rate: 69% or higher (go); 50-68% (amend); 49% or fewer (stop) 
 
Statistical Analysis 
Final analysis will take place once all participants have been followed-up for 52 weeks, and 
the database has been locked. Analyses will be by ‘intention to treat’ for the primary and 
secondary outcomes on all randomised participants, in the group to which they were 
allocated, and for whom the outcomes of interest have been observed or measured. 
Baseline  
Demographic and baseline characteristics will be summarised separately using descriptive 
statistics for each randomised group to allow clinical assessment of whether balance was 
achieved between randomised groups. No statistical testing of differences between groups 
will be performed.  
Analysis of effectiveness 
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Primary and secondary outcomes at baseline, 17 weeks’ and 52 weeks’ follow-up will be 
summarised for each treatment group using descriptive statistics at each time point. If 
normally distributed, the difference between group means (with 95% confidence intervals) 
will be reported from an analysis of covariance (ANCOVA) adjusted for baseline score and 
stratification factors.  
Missing data and withdrawals 
Predictors of missing data will be investigated using regression models (including type of 
surgery, age, living arrangements and co-morbidities) and any significant predictors will be 
considered for inclusion in the models. In addition, given the two assessment points at 17 
and 52 weeks, we will carry out a sensitivity analysis using a joint modelling approach to 
check whether there is any difference in outcome (here the longitudinal outcome rather 
than the outcome at 17 weeks or 52 weeks alone) between the randomised arms adjusted 
for dropouts or missing values.  
Instrumental variable regression 
The impact of engagement with the intervention will be assessed using instrumental 
variable (IV) regression, using the number of face-to-face direct rehabilitation sessions over 
52 weeks’ follow up as a continuous measure of engagement. Additional exploratory IV 
regression analyses will use in turn: the total number of rehabilitation sessions (face-to-face 
plus telephone), total time (in minutes) spent in face-to-face direct rehabilitation sessions, 
and total time (in minutes) spent in all rehabilitation sessions (i.e. face-to-face and 
telephone). The suitability of using randomisation as the instrument in these IV regression 
models will be assessed using tests of exogeneity, redundancy and under/weak 
identification. 
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Mediation analyses 
The hypothesised mechanism of change for the enhanced rehabilitation intervention is that 
participants’ primary outcome (activities of daily living) is mediated by self-efficacy, hip pain, 
cognitive function, fear of falling and physical function. If the enhanced rehabilitation 
intervention has a significant effect on primary outcome (p<0.05) for enhanced 
rehabilitation in ANCOVA, causal mediation analysis will be used to determine whether each 
of these potential mediators predict change in NEADL at 52 weeks. Initial assessments will 
determine whether the randomised intervention affects each putative mediator in turn. For 
those putative mediators that are significantly (p<0.1) affected by the randomised 
intervention, mediation analysis will be carried out adjusting for baseline covariates that 
predict both the mediator and NEADL, potentially including type of surgery, age, living 
arrangements (alone/with others) and co-morbidities. Sensitivity analyses will assess the 
potential impact of unmeasured confounding between the mediator and NEADL. 
 
Economic analysis 
The enhanced rehabilitation programme will be fully costed using unit costs from a public 
sector multiagency perspective. Unit costs will be obtained from national sources of 
reference costs [43,44] and applied to information received from pilot questionnaires, 
namely salary band of therapists, time spent with the patient conducting rehabilitation, 
costs of travel and costs of any additional equipment. Costs of health and social care 
services used by the participants will also be costed using national sources of reference 
costs. The costs of service use and the cost of the intervention will be added together for 
use in a cost-effectiveness analysis. 
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The EQ-5D (3L) will be used to calculate Quality Adjusted Life Years (QALYs) over the 52 
week trial period, using the area under the curve method [45,46]. A cost-utility analysis will 
be conducted to calculate a cost per QALY of the enhanced rehabilitation intervention. This 
cost per QALY generated will be compared to the NICE threshold range of £30,000 per QALY 
[47]. We will bootstrap differences in costs and outcomes (EQ-5D-3L) between the two 
groups, producing a 95% confidence interval around these differences. 
 
Process Evaluation 
The process evaluation will aim to identify and explain all mechanisms and processes (i.e. 
the intervention theory) that enabled or acted as a barrier to the implementation of the 
enhanced rehabilitation intervention. The process evaluation will help build a picture of how 
the intervention was carried out in reality, and what factors shaped it. By carrying out a 
process evaluation, it will be possible to identify if observed impacts are solely due to the 
enhanced rehabilitation programme, or if these impacts are a result of a number of external 
and internal variables that are closely linked to the environment and the context in which 
the intervention takes place [48-51]. 
The specific objectives will be to:  
• Refine the programme theory from the previous realist review that was used to 
develop the intervention [21]. This programme theory will explain how the 
researchers envisage the intervention to work, to reach its expected outcomes.  
• Investigate therapists’ expectations and experience of implementation, their 
previous experience and training, and their learning throughout the conduct of the 
trial. 
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• Investigate the mechanisms driving and shaping the tailoring of the enhanced 
rehabilitation intervention to individual patients.  
• Investigate trial participants’ (patients and carers) experiences and views about their 
involvement in the trial, as well as their experience of care in either arm of the trial.  
• Map and synthesise all data collected in order to test the refined programme theory 
and explain the trial findings.  
Process evaluation data collection 
Semi-structured telephone interviews will be conducted with:  
• A purposive sample of 60 patient participants in each of the two trial arms and up to 
30 of their carers. Patients will be purposively sampled to ensure diversity based on 
age, functional impairment (using baseline NEADL scores) and the presence or 
absence of a family carer. Interviews will take place after the 17-week assessment 
and will be audio recorded. 
• The therapists delivering the enhanced rehabilitation programme, which will explore 
implementation from the therapists’ perspectives. Interviews will be conducted  
midway through their involvement in the trial, and at the end, in order to investigate 
learning over time.  
Data on intervention delivery and adherence: 
• Therapists will record key reflections on ‘critical incident reports’.  
• The visiting therapist will record the length and content of each extra rehabilitation 
therapy session on a case report form.  
• All patient participants will be given a therapy session record, where visiting 
therapists will record the number, length and content of usual rehabilitation care. 
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Whenever possible, routinely collected electronic data that therapists complete on 
their Therapy Manager system, or its equivalent, will be collected.  
• An online questionnaire will be emailed to participating therapists in order to 
capture therapists’ relevant training, previous experience and familiarity with the 
trial intervention. 
Qualitative data will be analysed following a thematic analysis approach [52] that will be 
guided by the proposed programme theory. Quantitative data (record forms and online 
questionnaires) will be analysed using descriptive statistics, which will allow the exploration 
of frequency of responses. All data sets will be synthesised in order to describe the complex 
nature of the enhanced rehabilitation intervention.  
 
Patient and Public Involvement 
There has been patient and public involvement (PPI) at all stages including refining the 
research question, choosing outcomes relevant to patients, commenting on the burden of 
the intervention and of trial participation. A PPI co-investigator will continue to contribute 
to the trial management group, including comments on patient facing materials and the 
dissemination plan. 
 
Ethics and Dissemination 
NHS research ethics approval was obtained from North East – Tyne & Wear South Research 
Ethics Committee, reference 18/NE/0300. The current protocol is version 4.0 (11/12/20019). 
A Trial Steering Committee is providing overall supervision and an Independent Data Safety 
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and Monitoring Committee is responsible for reviewing and assessing recruitment, interim 
monitoring of safety and effectiveness, trial conduct and external data.   
 
All safety events will be recorded by researchers when they are made aware of the event by 
the patient, carer, the treating clinicians, or therapists. Adverse event reports and serious 
adverse events (SAEs) not related to the intervention will be entered on to the remote data 
entry system. Each SAE will be assessed by the relevant PI to determine whether it is related 
to the intervention. A related SAE will be assessed by the CI to determine whether it is 
expected. If the SAE is related and unexpected (RUSAE) it will be reported to the Research 
Ethics Committee (REC) and sponsor in an expedited manner. 
 
Reporting of the trial will be consistent with the CONSORT 2010 Statement (patient 
reported outcomes and non-pharmcological interventions) [53]. We will submit the final 
report to a peer-reviewed academic journal, according to our publication strategy and 
authorship policy. Research data will be available for secondary analysis upon reasonable 
request. 
 
Trial Status 
At the time of submission this trial had been open in nine sites and had recruited 96 patients 
and 10 carers, with a recruitment rate of two patient participants per site per month and a 
retention rate of 83%, which fulfilled the progression criteria of the internal pilot. However, 
recruitment to the trial is currently suspended because of the COVID-19 pandemic. 
Wherever possible, participants already recruited into the trial will complete their follow-up 
assessments over the telephone or by post, extra rehabilitation sessions will be delivered 
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over the telephone. When trial recruitment resumes, updated recruitment information will 
be found on the website http://femur3study.co.uk/ 
 
Abbreviations 
AMTS  Abbreviated Mental Test Score 
ANCOVA Analysis of Covariance 
CI  Chief Investigator 
CSI  Carer Strain Index 
CSRI  Client Service Receipt Inventory 
EQ-5D-3L EuroQol 5 Dimensions 3 Levels 
FEMuR  Fracture in the Elderly Multidisciplinary Rehabilitation 
FES-I  Falls Efficacy Scale - International  
GP  General Practitioner 
HADS  Hospital Anxiety and Depression Scale 
ISRCTN  International Standard Randomised Controlled Trial Number 
IV  Instrumental Variable   
LCTC  Liverpool Clinical Trials Centre 
NEADL  Nottingham Extended Activities of Daily Living 
NHS  National Health Service 
NICE  National Institute of Health and Clinical Excellence 
PI  Principal Investigator 
PPI  Patient and Public Involvement 
QALY  Quality Adjusted Life Year 
RCT  Randomised Controlled Trial 
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REC  Research Ethics Committee 
RUSAE  Related Unexpected Serious Adverse Event 
SAE  Serious Adverse Event 
SPPB  Short Physical Performance Battery 
VAS  Visual Analogue Scale 
VASFoF Visual Analogue Score - Fear of Falling  
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Table 1 Outcome measures 
Patient Completed Measures - Primary Description Range 
Nottingham Extended Activities of Daily 
Living (NEADL) scale [26, 27] 
Activities of daily living (mobility, kitchen, domestic, leisure) 
with higher score indicating greater independence 
(0-66)  
Patient Completed Measures - Secondary  
Hospital Anxiety and Depression Scale 
(HADS) [28] 
Anxiety and depression in patients with physical health 
problems. Two sub-scales (0-21) with higher score indicates 
greater anxiety or depression 
 (0-21)  
Patient Completed Economic Measures   
EuroQol EQ-5D-3L [29] Health utility index with five dimensions (mobility, self-care, 
usual activities, pain/discomfort, anxiety/depression) and 
three levels to give health states converted to a utility 
weight. Also Visual Analogue Score (VAS) for health state 
today 
Health utility weight from 0 
(death) to 1.0 (perfect health) 
also with negative values 
VAS (0-100) 
Client Service Receipt Inventory (CSRI) 
[30] 
Use of health and social care services According to activity 
Patient Completed Process Measures (potential mediators of outcomes)  
Visual Analogue Scale (VAS) for hip pain 
intensity [31] 
VAS of current hip pain intensity (0-10cm) 
Falls Efficacy Scale - International (FES-I) 
(self-efficacy) [32,33] 
How concerned a patient is about falling when performing 16 
activities of daily living both inside and outside of the home, 
rated from 1 (not at all concerned) to 4 (very concerned) 
(16-64) 
Visual Analogue Score - Fear of Falling 
(VASFoF) [34] 
VAS with higher scores indicating greater fear of falling (0-10cm) 
Assessment of cognitive function   
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Abbreviated Mental Test Score (AMTS) 
[35, 36] 
Detecting and monitoring cognitive impairment. 10 items 
with lower scores indicating worse cognitive function 
(0-10) 
Objective measures of physical function  
Grip strength [37] Hand dynamometer According to meter reading 
Short Physical Performance Battery 
(SPPB) [40,41] 
Physical function tests assessing lower limb function in terms 
of balance, gait, strength and endurance. Higher score 
indicates greater function 
(0-12) 
Carer completed measure - secondary outcome  
Caregiver Strain Index (CSI) [42] 13-items in the domains: employment, financial, physical, 
social and time. Positive responses to seven or more items 
indicate a greater level of strain 
(0-13) 
Hospital Anxiety and Depression Scale 
(HADS) [28] 
Anxiety and depression in carers. Two sub-scales (0-21) with 
higher score indicates greater anxiety or depression 
 (0-21)  
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Table 2 FEMuR III protocol schedule of forms and procedures 
Participant follow-up visits should take place at 17 (+/- 2 weeks) and 52 (+/- 2 weeks) weeks 
post randomisation.  
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Eligibility screening and 
consent        
Assessment of eligibility 
criteria X      
 Written and informed consent 
(patient / carer)) X      
Confirm consent   X X X X X 
Randomisation  X     
Discharge data   X     
Outcome measurement - 
patient       
  NEADL  X  X  X 
  HADS  X  X  X 
  AMTS  X  X  X 
  VAS hip pain intensity  X  X  X 
  FES-I  X  X  X 
  VASFoF   X  X  X 
  EQ-5D-3L  X  X  X 
  CSRI  X  X  X 
  Grip strength  X  X  X 
  SPPB    X  X 
Outcome measurement - 
carer       
  CSI  X  X  X 
  HADS  X  X  X 
Trial Intervention**   X    
Qualitative interviews       
Re-affirm consent verbally 
specifically for qualitative 
phone interview. (patient / 
carer) 
    X  
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Qualitative telephone 
interview     X  
Safety Event Reporting       
Monitoring of Adverse Events   X X X X 
Monitoring of Serious Adverse 
Events   X X X X 
 
* Randomisation and baseline should take place no later than 6 weeks after hip fracture 
repair surgery 
** If randomised to intervention arm. 
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Figure Legend 
 
Figure 1 Participant Flowchart for FEMuR III 
 
Appendix 1 FEMuR III Patient Participant Information Sheet and Informed Consent 
Forms 
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Appendix 2 FEMuR III Carer Participant Information Sheet and Informed Consent Forms 
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Appendix 3 FEMuR III Trial Registration Data 
 
Data category Information 
Registry and trial identification 
no. 
ISRCTN28376407 
Date of registration 23/11/2018 
Funder NIHR Evaluation, Trials and Studies Co-ordinating 
Centre (NETSCC); Grant code 16/167/09 
Sponsor University of Liverpool 
Contact for public enquiries LH email: femur3@liverpool.ac.uk 
Scientific title Fracture in the Elderly Multidisciplinary Rehabilitation - 
Phase III (FEMuR III): a definitive randomised 
controlled trial and economic evaluation of a 
community-based rehabilitation package following hip 
fracture 
Acronym FEMuR III 
Countries of recruitment United Kingdom 
Health condition Hip fracture 
Intervention Intervention comparator: Enhanced rehabilitation 
Control comparator: Usual care 
Inclusion criteria Aged 60 years or older 
Recent proximal hip fracture 
Surgical repair by replacement arthroplasty or internal 
fixation 
Living in own home prior to hip fracture 
Living and receiving rehabilitation from the NHS in the 
area covered by the trial centres 
Exclusion criteria Living in residential or nursing home prior to hip 
fracture 
Unable to understand English or Welsh 
Lacking mental capacity to give informed consent 
Study design Interventional 
Randomised controlled trial 
Treatment, education or self-management, 
psychological and behavioural, complex intervention, 
physical, rehabilitation 
Recruitment start date 01/04/2019 
Target sample size 446 
Primary outcome Nottingham Extended Activities of Daily Living scale 
Secondary outcomes EuroQol EQ-5D, Hospital Anxiety and Depression Scale, 
Abbreviated Mental Test Score, Falls Efficacy Scale – 
International, hip pain intensity, fear of falling, grip 
strength, short physical performance battery 
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